Epitope prediction is a critical component of modern vaccine design, helping researchers identify the specific parts of a pathogen’s proteins that can trigger a strong immune response. By analyzing the structure of antigens, computational tools are employed to predict which epitopes—small fragments of the antigen recognized by immune cells—are most likely to induce immunity. This is especially important for designing vaccines for pathogens that have high variability, like influenza or HIV. Accurate epitope prediction can significantly improve the efficacy of a vaccine, ensuring that it targets the most relevant components of a pathogen. This strategy not only enhances the immune response but also reduces the chances of the pathogen escaping immune detection due to mutations. As vaccine technology evolves, epitope prediction plays an increasingly important role in designing vaccines that provide broad protection, are more cost-effective, and can be rapidly adapted to emerging infectious diseases.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States